α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
Open Access
- 6 June 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1126
- https://doi.org/10.3389/fimmu.2019.01126
Abstract
NKT cells are CD1d-restricted innate-like T cells expressing both T cell receptor and NK cell markers. The major group of NKT cells in both human and mice is the invariant NKT (iNKT) cells and the best-known function of iNKT cells is their potent anti-tumor function in mice. Since its discovery 25 years ago, the prototype ligand of iNKT cells, α-galactosylceramide (α-GalCer) has been used in over 30 anti-tumor clinical trials with mostly suboptimal outcomes. To realize its therapeutic potential, numerous preclinical models have been developed to optimize the scheme and strategies for α-GalCer-based cancer immunotherapies. Nevertheless, since there is no standard protocol for α-GalCer delivery, we reviewed the preclinical studies with a focus on B16 melanoma model in the goal of identifying the best treatment schemes for α-GalCer treatment. We then reviewed the current progress in developing more clinically relevant mouse models for these preclinical studies, most notably the generation of new mouse models with a humanized CD1d/iNKT cell system. With ever-emerging novel iNKT cell ligands, invention of novel α-GalCer delivery strategies and significantly improved preclinical models for optimizing these new strategies, one can be hopeful that the full potential of anti-tumor potential for α-GalCer will be realized in the not too distant future.Keywords
Funding Information
- National Institutes of Health
This publication has 74 references indexed in Scilit:
- Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cellsProceedings of the National Academy of Sciences of the United States of America, 2013
- NKT Cells as an Ideal Anti-Tumor ImmunotherapeuticFrontiers in Immunology, 2013
- CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responsesCancer Immunology, Immunotherapy, 2012
- Analysis of the CD1 Antigen Presenting System in Humanized SCID MicePLOS ONE, 2011
- Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasisThe EMBO Journal, 2011
- Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cellsJournal of Immunological Methods, 2009
- Differential Recognition of CD1d-α-Galactosyl Ceramide by the Vβ8.2 and Vβ7 Semi-invariant NKT T Cell ReceptorsImmunity, 2009
- Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in miceJCI Insight, 2008
- Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cellsThe Journal of Experimental Medicine, 2007
- B16 as a Mouse Model for Human MelanomaCurrent Protocols in Immunology, 2000